PSY14 A PATIENT-LEVEL COST-EFFECTIVENESS ANALYSIS OF IRON ISOMALTOSIDE VERSUS FERRIC CARBOXYMALTOSE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN THE UNITED KINGDOM

Abstract

Intravenous iron is the recommended treatment for patients with iron deficiency anemia (IDA) where oral iron is ineffective or rapid iron replenishment is required. Two high-dose, rapid-administration intravenous iron formulations are currently available in the UK: iron isomaltoside 1000/ferric derisomaltose (IIM) and ferric carboxymaltose (FCM). An indirect treatment comparison (ITC) demonstrated that improvement from baseline hemoglobin was significantly larger with IIM than FCM. The objective was to use the ITC findings to evaluate the cost-effectiveness of IIM versus FCM from the perspective of a UK healthcare payer.